| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Booth Andrew, Chief Financial Officer
Received 50,000 shares by exercise or conversion ($16.1K) · Gave 50,000 shares as a gift |
| 13 Nov 2026 |
Form 4: Thermopylae Holdings Ltd., 10% owner
Gave 125,000 shares as a gift |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Booth Andrew, Chief Financial Officer
Bought 8,600 shares ($97.4K) |
| 12 Nov 2026 |
Form 4: Thermopylae Holdings Ltd., 10% owner
Bought 60,565 shares ($699K) |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indica... |
| 24 Aug 2026 |
Form 4: Hayden Michael R, Director
Bought 53,613 shares ($570K) |
| 18 Aug 2026 |
Form 4: Montalbano John S., Director
Bought 10,000 shares ($110K) |
| 14 Aug 2026 |
Form 4: Booth Andrew, Chief Financial Officer
Bought 37,200 shares ($384K) |
| 14 Aug 2026 |
Form 4: Hayden Michael R, Director
Bought 46,387 shares ($481K) |
| 13 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. AbCellera Biologics Inc., a corporation incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i... |
| 13 Aug 2026 | 424B5 |
| 13 Aug 2026 |
Form 4: Hayden Michael R, Director
Gave 50,000 shares as a gift |
| 11 Aug 2026 | 424B5 |
| 10 Aug 2026 |
8-K: Regulation FD Disclosure
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking... |
| 07 Aug 2026 |
8-K: Other Events
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to- Severe VMS Due to Menopause on Monday, August 10,... |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indic... |
| 29 Jul 2026 |
8-K: Other Events
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Announces Collaboration with Vertex to Discover Multispeci�c T-Cell Engagers for Autoimmune Diseases and Other Conditions 2026-07-29 VANCOUVER, Br... |
Loading...